Table 2.
Cellular immunogenicity outcomes against wild-type SARS-CoV-2 after the third dose of BNT162b2 in the evaluable analysis population
| Adolescents three doses | Adults three doses | |
|---|---|---|
| T cell responses | ||
| S-specific T cell responses on flow cytometry | ||
| N | 26 | 28 |
| GM % IFN-γ+CD4+ T cells (95% CI) | 0.058% (0.031–0.111%) | 0.054% (0.027–0.106%) |
| % positive (≥cut-off at 0.01%) | 88.5%, P = 0.71 | 82.1% |
| GM % IL-2+CD4+ T cells (95% CI) | 0.046% (0.022-0.095%) | 0.040% (0.021–0.075%) |
| % positive (≥cut-off at 0.01%) | 80.8%, P > 0.9999 | 78.6% |
| GM % IFN-γ+CD8+ T cells (95% CI) | 0.045% (0.023–0.091%) | 0.016% (0.006–0.038%) |
| % positive (≥cut-off at 0.01%) | 84.6%, P = 0.002 | 42.9% |
| GM % IL-2+CD8+ T cells (95% CI) | 0.027% (0.012–0.059%) | 0.010% (0.005–0.020%) |
| % positive (≥cut-off at 0.01%) | 76.9%, P = 0.052 | 50.0% |
| % positive with at least 1 cytokine and subset (IFN-γ+/IL-2+CD4/8+) | 100%, P = 0.011 | 85.7% |
P values compare the proportion of positive responses between adolescents and adults by Fisher’s exact test
S Spike, GM geometric mean, CI confidence interval, IFN-γ interferon-gamma, IL-2 interleukin-2